Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

The DNA data of more than 15 million customers of DNA testing firm 23andMe is set to be returned to the control of 23andMe co ...

23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the business after emerging ...

Anne Wojcicki, former chief executive of 23andMe, won a bid to acquire the genetic testing company she founded in a second ...

This trial evaluated the safety and efficacy of the combination of Regeneron’s Lynozyfic (linvoseltamab), a B-cell maturation ...

TTAM Research Institute, a non-profit public benefit company also founded by Wojcicki, won the auction with a $305 million ...

23andMe struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, ...

Anne Wojcicki won a bid to purchase the genetic testing platform through her nonprofit TTAM Research Institute. The $305M deal was part of a bankruptcy auction, beating out offers from Regeneron ...

UnitedHealth Group ( UNH -1.61%) was the worst-performing stock in the S&P 500 last month. It plunged 26.6% to 52-week lows of $248.88 per share on May 15 after CEO Andrew Witty abruptly resigned and ...

On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...

The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks.

Several states have joined a lawsuit against 23andme. They say bankruptcy shouldn't allow the genetic testing company to sell ...